Your browser is no longer supported. Please, upgrade your browser.
ANIK [NASD]
Anika Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own0.40% Shs Outstand14.28M Perf Week4.57%
Market Cap594.28M Forward P/E46.78 EPS next Y0.91 Insider Trans-5.81% Shs Float13.99M Perf Month5.37%
Income-24.00M PEG- EPS next Q-0.07 Inst Own98.80% Short Float12.07% Perf Quarter11.12%
Sales130.50M P/S4.55 EPS this Y-189.10% Inst Trans1.79% Short Ratio11.14 Perf Half Y30.62%
Book/sh19.07 P/B2.23 EPS next Y1922.22% ROA-1.10% Target Price48.00 Perf Year36.14%
Cash/sh7.04 P/C6.05 EPS next 5Y10.00% ROE-1.50% 52W Range27.53 - 47.47 Perf YTD-5.94%
Dividend- P/FCF26.89 EPS past 5Y-23.20% ROI-8.70% 52W High-10.33% Beta1.22
Dividend %- Quick Ratio3.60 Sales past 5Y7.00% Gross Margin52.90% 52W Low54.60% ATR1.47
Employees277 Current Ratio4.80 Sales Q/Q9.70% Oper. Margin-4.20% RSI (14)59.81 Volatility3.48% 3.50%
OptionableYes Debt/Eq0.00 EPS Q/Q-497.70% Profit Margin-3.30% Rel Volume0.45 Prev Close41.50
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume151.55K Price42.57
Recom1.00 SMA203.82% SMA509.57% SMA20012.46% Volume67,650 Change2.58%
Dec-16-20Upgrade Barrington Research Mkt Perform → Outperform $43
May-08-20Downgrade Barrington Research Outperform → Mkt Perform
Jan-21-20Upgrade Sidoti Neutral → Buy $61
Jan-10-20Upgrade First Analysis Sec Outperform → Strong Buy $65
Nov-05-19Initiated BWS Financial Sell $29
Sep-24-19Reiterated Barrington Research Outperform $49 → $58
Sep-23-19Downgrade First Analysis Sec Strong Buy → Outperform $54
Jul-25-19Upgrade First Analysis Sec Neutral → Strong Buy $37 → $54
Feb-22-19Downgrade Sidoti Buy → Neutral $56 → $41
Feb-22-19Downgrade First Analysis Sec Outperform → Neutral $41 → $37
Jul-27-18Upgrade Barrington Research Mkt Perform → Outperform $48
Jun-20-18Downgrade First Analysis Sec Overweight → Equal-Weight $45 → $34
Jun-20-18Downgrade Barrington Research Outperform → Mkt Perform
May-04-18Upgrade Barrington Research Mkt Perform → Outperform $39
Feb-23-18Downgrade Barrington Research Outperform → Mkt Perform
Jan-24-18Upgrade First Analysis Sec Equal-Weight → Overweight $45 → $68
Oct-27-17Reiterated Barrington Research Outperform $53 → $57
May-09-16Upgrade Singular Research BUY - Long-Term → Buy $60
Apr-27-16Downgrade Northland Capital Outperform → Market Perform
Feb-26-16Reiterated Barrington Research Outperform $45 → $49
May-07-21 04:31AM  
May-06-21 08:05PM  
04:05PM  
May-04-21 10:30AM  
Apr-15-21 05:15PM  
Apr-05-21 09:25AM  
Mar-30-21 11:28AM  
Mar-23-21 07:30PM  
Mar-11-21 12:15PM  
Mar-09-21 09:02AM  
Mar-06-21 01:21AM  
Mar-04-21 10:30PM  
07:25PM  
04:50PM  
04:05PM  
02:45PM  
Feb-28-21 01:47AM  
Feb-09-21 03:00PM  
Jan-04-21 08:22AM  
Dec-30-20 12:03AM  
Dec-21-20 08:46AM  
Dec-16-20 06:47PM  
Nov-09-20 08:46AM  
Nov-04-20 09:32PM  
07:05PM  
04:05PM  
03:15PM  
Oct-31-20 08:25AM  
Oct-28-20 12:32PM  
Oct-22-20 04:05PM  
Oct-21-20 04:05PM  
Oct-15-20 12:31PM  
Sep-24-20 11:40AM  
Sep-08-20 04:53PM  
Sep-07-20 11:40AM  
Sep-03-20 02:34PM  
Aug-21-20 11:40AM  
Aug-10-20 07:55AM  
07:55AM  
Aug-05-20 04:09PM  
11:40AM  
Aug-04-20 11:00AM  
Jul-30-20 07:30PM  
07:10PM  
04:05PM  
Jul-23-20 12:32PM  
Jul-20-20 07:00AM  
Jul-16-20 04:05PM  
Jul-15-20 12:31PM  
Jun-23-20 11:50AM  
Jun-02-20 04:05PM  
May-12-20 04:05PM  
May-08-20 11:00PM  
12:00PM  
May-07-20 04:05PM  
May-01-20 06:34AM  
Apr-28-20 11:40AM  
Apr-27-20 08:30AM  
Apr-23-20 04:05PM  
Apr-08-20 04:05PM  
Apr-02-20 12:45PM  
Mar-26-20 06:12AM  
Mar-11-20 07:51AM  
Mar-04-20 08:30AM  
Feb-27-20 07:52AM  
Feb-21-20 07:46AM  
Feb-20-20 07:15PM  
04:05PM  
Feb-13-20 12:31PM  
Feb-12-20 04:05PM  
Feb-06-20 05:14PM  
Feb-04-20 05:38AM  
Feb-03-20 04:30PM  
Jan-29-20 04:30PM  
Jan-24-20 04:05PM  
Jan-13-20 03:00PM  
Jan-08-20 11:47AM  
Jan-06-20 08:30AM  
Dec-30-19 08:22AM  
Dec-24-19 08:57AM  
Dec-20-19 09:28AM  
Dec-19-19 11:35AM  
10:18AM  
10:02AM  
Dec-17-19 10:25AM  
Dec-16-19 03:44PM  
09:46AM  
08:42AM  
08:05AM  
Dec-13-19 09:25AM  
Dec-12-19 03:19PM  
02:34PM  
09:36AM  
Dec-11-19 04:11PM  
02:42PM  
10:06AM  
08:40AM  
Dec-10-19 09:26AM  
08:30AM  
Dec-09-19 04:31PM  
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blanchard Cheryl RPresident, CEO, DirectorApr 26Option Exercise0.0024,575034,478Apr 28 05:00 PM
Colleran DavidEVP, General Counsel, Corp SecMar 04Option Exercise0.002,50002,500Mar 08 05:06 PM
Finnerty ThomasEVP Human ResourcesFeb 26Option Exercise0.003,000012,582Mar 01 05:18 PM
Loerop JamesEVP Business DevelopmentFeb 25Option Exercise0.001,56703,323Mar 01 05:19 PM
Finnerty ThomasEVP Human ResourcesFeb 25Option Exercise0.002,833010,414Mar 01 05:18 PM
LAND RAYMOND JDirectorNov 10Sale36.773,446126,7099,953Nov 12 04:08 PM
Loerop JamesEVP Business DevelopmentJul 09Sale35.151,24443,7271,756Jul 10 04:06 PM